港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

生物医药B类股

728.939

-15.659-2.10%

涨家数：14

跌家数：18

平家数：2

市盈率：- -

高：744.967

开：744.496

低：723.794

收：744.598

数据加载中...

华检医疗涨超8% 近日披露跨界Web3与创新药融资模式战略 RWA助推创新资产转化

港股异动 | 科济药业-B(02171.HK)回落逾4% 预期上半年净亏损不超过8000万元较去年同期显著收窄

ETF午评 | 生物医药板块全面上涨，港股医疗ETF涨2%

创新药暴涨之后到位了吗？汇丰：下半年还有三大催化剂

华尔街见闻

港股异动 | 中国抗体-B涨超19%，配股筹资3.69亿港元用于临床试验

先瑞达医疗-B盘中异动股价大涨5.00%报13.440港元

港股异动 | 中国抗体-B(03681.HK)再涨超20% 公司配股筹资净筹3.69亿港元拟用于SM03临床试验等项目

归创通桥再涨近6% 预计中期纯利同比增长66.9% 公司拥抱集采并积极布局海外

中生制药早盘涨逾4% 本月内累计涨幅已超30%

心通医疗-B盘中异动早盘股价大涨5.51%

港股异动 | 医疗器械股早盘走高国家药品集采明确反内卷机构看好行业拐点机会

港股异动 | 中生制药(01177.HK)再涨超4% 附属礼新医药LM-350获得美国FDA的IND批件

药明巨诺-B盘中异动大幅拉升5.10%报4.120港元

《股市简讯》中国生物科技公司云顶新耀大跌7.5%，拟折让约一成配售新股

归创通桥盘中异动急速上涨5.15%报23.500港元

贝康医疗-B盘中异动早盘股价大涨6.38%

同源康医药-B盘中异动早盘股价大涨5.00%

【券商聚焦】中信建投：港股医疗器械公司整体创新性较强多家企业即将步入扭亏为盈或业绩快速释放的阶段

第3项！康方生物PD-1/VEGF双抗新适应症申报上市

云顶新耀(01952.HK)宣布配售股份拟集资约15.725亿港元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK1574/news?page=3"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":728.93866,"timestamp":1753430886241,"preClose":744.5975,"halted":0,"volume":295989198,"delay":0,"changeRate":-0.02103,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-15.658813,"latestTime":"07-25 16:00:00","open":744.49634,"high":744.967,"low":723.794,"amount":7101826928,"amplitude":0.028435,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1753407000000,1753416000000],[1753419600000,1753430400000]],"pbRate":5.862148,"peRate":-36.113023,"turnoverRate":0.011111,"increases":13,"decrements":20,"flats":0,"marketCap":427345468672,"floatMarketCap":392843141040},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":744.967,"amplitude":0.028435,"preClose":744.5975,"low":723.794,"pbRate":"5.862148","latestPrice":728.93866,"volume":295989198,"delay":0,"open":744.49634,"prevYearClose":331.1933,"prevWeekClose":711.682,"prevMonthClose":555.617,"prevQuarterClose":555.617,"fiveDayClose":711.682,"twentyDayClose":566.494,"sixtyDayClose":466.153,"secType":"PLATE","market":"HK","turnoverRate":0.011111,"peRate":-36.113023,"marketCap":427345468672,"floatMarketCap":392843141040,"timestamp":1753430886241,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":14,"down":18,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2554753123","title":"华检医疗涨超8% 近日披露跨界Web3与创新药融资模式战略 RWA助推创新资产转化","url":"https://stock-news.laohu8.com/highlight/detail?id=2554753123","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554753123?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 11:52","pubTimestamp":1753415535,"startTime":"0","endTime":"0","summary":"据了解，在医疗创新药领域，RWA的应用前景尤为广阔。而在华检医疗的战略规划中，RWA技术可将Ⅱ期临床的ADC药物、基因疗法等创新资产转化为可分割交易的数字凭证。传统模式下，一款新药90%价值被上市后资本收割；而通过RWA代币化，早期研发阶段投资者可分享临床试验成功的里程碑收益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725121241a4627f03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725121241a4627f03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1197","BK1574","01931","06978"],"gpt_icon":0},{"id":"2554758159","title":"港股异动 | 科济药业-B(02171.HK)回落逾4% 预期上半年净亏损不超过8000万元 较去年同期显著收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2554758159","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554758159?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 11:40","pubTimestamp":1753414815,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1585","02171","BK1574","BK1587"],"gpt_icon":0},{"id":"2554758619","title":"ETF午评 | 生物医药板块全面上涨，港股医疗ETF涨2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554758619","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554758619?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 11:39","pubTimestamp":1753414744,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["159619","07226","399001","BK4614","516020","515000","BK1574","399441","BK1583","BK4585","159688","HSCEI","BK4550","513330","516950","09997","516630","161715","515120","562600","159745","159945","512170","159828","FDN","BK1222","516750","588730","09996","159883","159982","399006","BK1100","159702","YANG","399300","BK4588","159715","HSTECH","159870","510410","000979.SH","161726"],"gpt_icon":0},{"id":"2554500737","title":"创新药暴涨之后到位了吗？汇丰：下半年还有三大催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2554500737","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554500737?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 11:37","pubTimestamp":1753414629,"startTime":"0","endTime":"0","summary":"汇丰认为，下半年即将密集公布的学术成果、持续涌现的海外业务发展（BD）交易，以及政策面的支持将支撑医药板块的上涨势头。中国创新药企的价值潜力尚未被市场完全消化，未来仍有进一步上行空间。","market":"us","thumbnail":"https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49"],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3751855","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3751855","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2236285917.USD","03692","BK4585","BK1574","BK4521","LU0128525689.USD","01801","BK4588","LU1267930227.SGD","LU0052756011.USD","02269","01177","LU0310800965.SGD","BK4207"],"gpt_icon":1},{"id":"1107966336","title":"港股异动 | 中国抗体-B涨超19%，配股筹资3.69亿港元用于临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1107966336","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107966336?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 11:34","pubTimestamp":1753414492,"startTime":"0","endTime":"0","summary":"7月25日，中国抗体-B盘中涨超19%，公司配股筹资净筹3.69亿港元，拟用于SM03临床试验等项目。消息面上，中国抗体公告，拟发行1.82亿股新股份，认购价为每股2.03港元。该决定乃经内部评估后作出，该评估确定需要补充早期疗效的证据以支持BLA的审批。公司对舒西利单抗获批准于中国上市仍具信心，已开始规划舒西利单抗用于治疗系统性红斑狼疮的新临床开发计划。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b43aa50d154816676350b6a417348f58","theme_name":"🔥热榜No.17 · 中国抗体-B股价异动","theme_type":2,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1321863.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1583","BK1141","03681","BK1161","BK1574","BK1576","BK4614"],"gpt_icon":0},{"id":"2554758903","title":"先瑞达医疗-B盘中异动 股价大涨5.00%报13.440港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554758903","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554758903?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 11:31","pubTimestamp":1753414296,"startTime":"0","endTime":"0","summary":"2025年07月25日临近午盘11时31分，先瑞达医疗-B股票出现波动，股价大幅拉升5.00%。截至发稿，该股报13.440港元/股，成交量34.5万股，换手率0.11%，振幅6.25%。资金方面，该股资金流入302.442万港元，流出106.282万港元。先瑞达医疗-B股票所在的医疗设备及用品行业中，整体涨幅为0.20%。先瑞达医疗-B公司简介：先瑞达医疗科技控股有限公司是一家介入医疗器械中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725113136a6c0c9f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725113136a6c0c9f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06669","BK1100","BK1587"],"gpt_icon":0},{"id":"2554675834","title":"港股异动 | 中国抗体-B(03681.HK)再涨超20% 公司配股筹资净筹3.69亿港元 拟用于SM03临床试验等项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2554675834","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554675834?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 11:25","pubTimestamp":1753413958,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b43aa50d154816676350b6a417348f58","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1141","BK1161","BK1574","03681","03347","BK1576"],"gpt_icon":0},{"id":"2554758805","title":"归创通桥再涨近6% 预计中期纯利同比增长66.9% 公司拥抱集采并积极布局海外","url":"https://stock-news.laohu8.com/highlight/detail?id=2554758805","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554758805?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 10:45","pubTimestamp":1753411511,"startTime":"0","endTime":"0","summary":"归创通桥再涨近6%，截至发稿，涨2.91%，报23港元，成交额909.88万港元。消息面上，归创通桥公布，预期截至今年6月底止六个月的收入将超过4.8亿元人民币，同比增长约31.1%，去年同期为3.66亿元人民币。集团预计今年首六个月的纯利将超过1.15亿元人民币，同比增长约66.9%。华创证券指出，归创通桥在神经介入、外周介入产品线布局全面，截止今年3月20日，公司共战略布局66款产品及候选产品，已在国内商业化产品共计47款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725110406a4625f49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725110406a4625f49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02190","BK1100","BK1587","BK1583","BK1574"],"gpt_icon":0},{"id":"2554756535","title":"中生制药早盘涨逾4% 本月内累计涨幅已超30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554756535","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554756535?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 10:07","pubTimestamp":1753409220,"startTime":"0","endTime":"0","summary":"　　中生制药盘中涨超4%，本月内累计涨幅已超30%。截至发稿，股价上涨3.88%，现报6.97港元，成交额4.23亿港元。　　中国生物制药公布，全资附属公司礼新医药自主研发的创新药LM-350“CDH17 ADC”已获得美国食品药品监督管理局的新药临床试验批件。公司指，除LM-350外，集团还有5款抗体偶联药物产品位于临床阶段。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-07-25/doc-infhrzee5203024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1191","01477"],"gpt_icon":0},{"id":"2554376047","title":"心通医疗-B盘中异动 早盘股价大涨5.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554376047","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554376047?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 10:03","pubTimestamp":1753409030,"startTime":"0","endTime":"0","summary":"2025年07月25日早盘10时03分，心通医疗-B股票出现波动，股价大幅拉升5.51%。截至发稿，该股报1.340港元/股，成交量422.1万股，换手率0.17%，振幅7.09%。心通医疗-B股票所在的医疗设备及用品行业中，整体涨幅为0.28%。其相关个股中，永胜医疗、爱康医疗、威高股份涨幅较大，振幅较大的相关个股有永胜医疗、春立医疗、微创医疗，振幅分别为13.64%、12.86%、11.66%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725100351a4623f70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725100351a4623f70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1100","BK1583","02160"],"gpt_icon":0},{"id":"2554327147","title":"港股异动 | 医疗器械股早盘走高 国家药品集采明确反内卷 机构看好行业拐点机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2554327147","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554327147?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 10:00","pubTimestamp":1753408859,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1617","01066","01612","BK0251","BK1574","159883","BK1222","01789","01858","BK1585","LU0173614495.USD","LU0287142896.SGD","BK1100","09997","00853","BK1589","688236","BK1583","09996"],"gpt_icon":0},{"id":"2554327677","title":"港股异动 | 中生制药(01177.HK)再涨超4% 附属礼新医药LM-350获得美国FDA的IND批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2554327677","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554327677?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:59","pubTimestamp":1753408758,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["159938","BK1191","BK1589","BK1574","01177","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","01477","BK1515","BK1161","BK1521","09939","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2554732755","title":"药明巨诺-B盘中异动 大幅拉升5.10%报4.120港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554732755","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554732755?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:53","pubTimestamp":1753408423,"startTime":"0","endTime":"0","summary":"2025年07月25日早盘09时53分，药明巨诺-B股票出现波动，股价急速上涨5.10%。截至发稿，该股报4.120港元/股，成交量78.15万股，换手率0.19%，振幅6.89%。资金方面，该股资金流入146.762万港元，流出117.591万港元。药明巨诺-B股票所在的生物技术行业中，整体涨幅为0.99%。其相关个股中，维立志博-B、中国抗体-B、药明生物涨幅较大，振幅较大的相关个股有维立志博-B、奥星生命科技、中国抗体-B，振幅分别为21.00%、17.78%、12.17%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725095344971d36a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725095344971d36a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02126","BK1583","BK1574","BK1161"],"gpt_icon":0},{"id":"2554732377","title":"《股市简讯》中国生物科技公司云顶新耀大跌7.5%，拟折让约一成配售新股","url":"https://stock-news.laohu8.com/highlight/detail?id=2554732377","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554732377?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:51","pubTimestamp":1753408274,"startTime":"0","endTime":"0","summary":"《股市简讯》中国生物科技公司云顶新耀大跌7.5%，拟折让约一成配售新股* 中国生物科技公司--云顶新耀1952.HK周五早盘低开5.9%，随后跌幅扩大至7.5%。* 该公司稍早公告称，拟配售2,256.1万股新股，配售价69.7港元，较周四收市价折让约10.12%，筹15.7亿港元，拟用于管线产品的全球研发、商业化推进工作、公司营运及一般行政管理开支。* 云顶新耀今年迄今大涨48.5%，同期恒生指数.HSI大幅上扬27.1%。* 恒生香港上市生物科技指数.HSHKBIO盘中一度升1.6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250725:nL4S3TM03T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01952","BK1583","BK1161"],"gpt_icon":0},{"id":"2554737984","title":"归创通桥盘中异动 急速上涨5.15%报23.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554737984","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554737984?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:47","pubTimestamp":1753408056,"startTime":"0","endTime":"0","summary":"2025年07月25日早盘09时47分，归创通桥股票出现异动，股价大幅上涨5.15%。截至发稿，该股报23.500港元/股，成交量11.7万股，换手率0.04%，振幅4.92%。归创通桥股票所在的医疗设备及用品行业中，整体涨幅为0.03%。该信息摘要如下：归创通桥宣布，公司将于2025年8月19日（星期二）举行董事会会议，藉以审议及批准公司及其附属公司截至2025年6月30日止六个月的中期业绩及其发布，以及处理其他事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725094736a6c0945f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725094736a6c0945f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1100","BK1574","02190","BK1583"],"gpt_icon":0},{"id":"2554737647","title":"贝康医疗-B盘中异动 早盘股价大涨6.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554737647","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554737647?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:46","pubTimestamp":1753408013,"startTime":"0","endTime":"0","summary":"2025年07月25日早盘09时46分，贝康医疗-B股票出现波动，股价大幅拉升6.38%。截至发稿，该股报3.000港元/股，成交量6000股，换手率0.01%，振幅5.67%。贝康医疗-B股票所在的生物技术行业中，整体涨幅为0.17%。贝康医疗-B公司简介：苏州贝康医疗股份有限公司是一家主要提供辅助生殖基因检测解决方案的中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072509465394b96e16&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072509465394b96e16&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1597","BK1574","02170","BK1222"],"gpt_icon":0},{"id":"2554732832","title":"同源康医药-B盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554732832","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554732832?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:32","pubTimestamp":1753407161,"startTime":"0","endTime":"0","summary":"2025年07月25日早盘09时32分，同源康医药-B股票出现波动，股价快速拉升5.00%。同源康医药-B股票所在的生物技术行业中，整体涨幅为0.76%。其相关个股中，维立志博-B、中国抗体-B、奥星生命科技涨幅较大，振幅较大的相关个股有维立志博-B、奥星生命科技、北海康成-B，振幅分别为21.00%、8.89%、5.33%。同源康医药-B公司简介：浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072509324194b96701&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072509324194b96701&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","02410","09939","BK1161","BK1574"],"gpt_icon":0},{"id":"2554731461","title":"【券商聚焦】中信建投：港股医疗器械公司整体创新性较强 多家企业即将步入扭亏为盈或业绩快速释放的阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2554731461","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554731461?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 08:56","pubTimestamp":1753405002,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投发研报指，港股医疗器械公司整体创新性较强，多家企业即将步入扭亏为盈或业绩快速释放的阶段。今年以来，有创新产品上市、技术突破实现license-out可能的催化，以及账上现金丰富、业绩快速释放、估值低位的部分18A器械公司，年初至今有翻倍以上的涨幅；部分业绩高增长的低估值龙头器械公司年初至今亦有较好表现。映射到A股医疗器械投资，我们亦看好器械集采政策优化、创新产品上市放量及国际业务高增长个股的投资机会，预计下半年多家企业将迎来业绩拐点，Q3业绩有望实现高增长。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1962857","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","HSCEI","HSTECH","BK1593","02252","BK1574","BK4614","BK1222","BK1617","BK1583","02172","YANG","159883","601066","09996","BK1161","06826","09997","BK1100","06609","BK0276"],"gpt_icon":0},{"id":"2554312167","title":"第3项！康方生物PD-1/VEGF双抗新适应症申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2554312167","media":"医药魔方","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554312167?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 08:41","pubTimestamp":1753404089,"startTime":"0","endTime":"0","summary":"7月25日，国家药品监督管理局药品审评中心官网显示，康方生物的依沃西单抗新适应症上市申请已获受理。依沃西单抗是康方生物自主研发的、全球首创PD-1/VEGF双特异性肿瘤免疫治疗药物。此次申报的适应症为第3项。与治疗相关的严重不良反应发生率以及三级及以上出血事件发生率与对照组相似。HARMONi-6研究是依沃西在非小细胞肺癌领域取得的第3个显著阳性结果的III期临床研究，填补了抗血管生成机制药物在sq-NSCLC中不可用的巨大临床空白。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725085834971d1d1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725085834971d1d1e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0417516571.SGD","BK1161","LU1720050803.USD","BK1574","09926","LU0348783233.USD","LU0348784397.USD","IE00B543WZ88.USD","LU2488822045.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2554373193","title":"云顶新耀(01952.HK)宣布配售股份 拟集资约15.725亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554373193","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554373193?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 08:37","pubTimestamp":1753403868,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01952","BK1574","BK1583","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":32,"pageCount":3,"totalSize":640,"code":"91000000","status":"200"}]}}